Publications by authors named "Tomoki Suizu"
Cancer Control
October 2022
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are linked to better survival rates in cancer patients, particularly those experiencing immune-related adverse events (irAEs).
- A study analyzed 200 patients with non-small-cell lung cancer, gastric cancer, and melanoma, finding that those with irAEs had improved overall survival (OS) and progression-free survival (PFS) compared to those without.
- Factors such as age, albumin levels, and smoking history were associated with a higher risk of developing irAEs, which were mostly mild (grade ≤2), and common irAEs included pneumonitis and thyroiditis.
